All In Biotech

Drug Trial Radar · NCT07609719

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

A Prospective, Multicenter, Single-arm Study of Ocrelizumab Administered Subcutaneously in Patients With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 2, 2026

Primary completion

Feb 28, 2029

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).

Conditions

  • Multiple Sclerosis

Interventions

  • OCR SCDrug

    Participants will receive OCR SC as per the schedule specified in the arm and the United States Prescribing Information (USPI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With no Change or Reduction From Baseline in Number of T1 Gadolinium-enhanced (Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Week 24Time frame: Baseline, Week 24

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Neurology Associates

    Birmingham, Alabama · Recruiting

  • Clinical Endpoints, LLC

    Scottsdale, Arizona · Recruiting

  • Advanced Neurology of Colorado, LLC

    Fort Collins, Colorado · Recruiting

  • Neurology Associates, PA

    Maitland, Florida · Recruiting

  • Atlanta Neuroscience Institute

    Atlanta, Georgia · Recruiting

  • Savannah Neurology Specialists,PC

    Savannah, Georgia · Recruiting

  • Neurology Clinic PC

    Cordova, Tennessee · Recruiting

  • Caribbean Center for Clinical Research

    Guaynabo, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.